Choong-kun L. Lee

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications

Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.

Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 27, 2026

Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies.

Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies.

Journal: JNCI cancer spectrum
Published: February 09, 2026

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.

Journal: BMC cancer
Published: December 26, 2025

A 3D pooled PBMC-organoid co-culture platform for profiling immune susceptibility and PD-1 blockade response in gastric cancer.

A 3D pooled PBMC-organoid co-culture platform for profiling immune susceptibility and PD-1 blockade response in gastric cancer.

Journal: BMC medicine
Published: December 23, 2025

A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.

A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.

Journal: Cancer research and treatment
Published: December 10, 2025

Molecular and Phenotypic Characterization of Fluid-Derived Patient-Derived Cell and Organoid Models in Advanced Gastric Cancer.

Molecular and Phenotypic Characterization of Fluid-Derived Patient-Derived Cell and Organoid Models in Advanced Gastric Cancer.

Journal: Journal of gastric cancer
Published: November 10, 2025

Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.

Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.

Journal: Scientific reports
Published: October 15, 2025

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

Journal: BMC cancer
Published: October 11, 2025

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Journal: JCO precision oncology
Published: October 02, 2025

Tie2 Activation Enhances Vascularized Lymph Node Transfer in Lymphedema by Improving Lymphatic Endothelial Integrity.

Tie2 Activation Enhances Vascularized Lymph Node Transfer in Lymphedema by Improving Lymphatic Endothelial Integrity.

Journal: Plastic and reconstructive surgery
Published: September 24, 2025

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer.

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer.

Journal: Clinical and molecular hepatology
Published: September 09, 2025

Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial.

Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial.

Journal: EClinicalMedicine
Published: August 23, 2025
Showing 1-12 of 91

Last Updated: 09/26/2026